Bacteriophage structural proteins via cell-free expression system
Summary
The USPTO published patent application US20260092261A1 for multi-peptide structures comprising heterologous functional sites derived from bacteriophage structural proteins produced via cell-free expression. The application, filed by Elisabeth Falgenhauer and co-inventors Friedrich Simmel, Kilian Vogele, and Sophie von Schönberg, covers compositions and methods for universal anti-microbial applications in medicine, chemistry, biotechnology, agriculture, and food industry.
What changed
The USPTO published patent application US20260092261A1 covering multi-peptide structures with heterologous functional sites composed of at least two homologous peptides differing by at least one amino acid. The invention specifically relates to bacteriophage structural proteins produced through cell-free expression systems. CPC classifications span C12N 7/00 (viruses), C07K 14/005 (peptides), and A61K 38/00 (medicinal preparations), with applications in anti-microbial agents targeting A61P 31/04 (anti-infectives).\n\nThis patent application represents a technical innovation in synthetic biology and antimicrobial development. Companies developing bacteriophage-based therapeutics, antimicrobial coatings, or food safety applications should review the claims for potential freedom-to-operate implications. Research institutions and biotech firms working in this space should assess whether the disclosed cell-free expression methods overlap with their own R&D activities.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
SIMULTANEOUS PRODUCTION OF STRUCTURAL PROTEINS FROM HETEROLOGOUS BACTERIOPHAGE IN CELL-FREE EXPRESSION SYSTEM
Application US20260092261A1 Kind: A1 Apr 02, 2026
Assignee
Elisabeth FALGENHAUER
Inventors
Friedrich SIMMEL, Kilian VOGELE, Sophie VON SCHÖNBERG
Abstract
The present invention relates to multi-peptide structures comprising at least one heterogenous functional site wherein the at least one heterogenous functional site is composed of at least two homologous peptides, which differ by at least one amino acid, a method for providing such multi-peptide structures, compositions comprising such multi-peptide structures as well as the use of such multi-peptide structures and compositions as an universal anti-microbial agent, in particular in medicine, chemistry, biotechnology, agriculture and/or food industry.
CPC Classifications
C12N 7/00 A61K 38/00 A61P 31/04 C07K 14/005 C12N 2795/00021 C12N 2795/00022 C12N 2795/00032 C12N 2795/00033 C12N 2795/00051
Filing Date
2023-09-20
Application No.
19113612
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.